Cancer Immune Therapy Edited by G. Stuhler and P. Walden ...

four C022 antibodies as ricin A-chain
containing immunotoxins for the in
vivo therapy of human B-cell leukemias
and lymphomas. Int J Cancer 42: 792±7.
35 Blakey OS,Watson GJ, Knowles PP,
et al. (1987) Effect of chemical deglycosylation
of ricin A-chain on the in vivo
fate and cytotoxic activity of an immunotoxin
composed of ricin A-chain and
anti-Thy 1. 1 antibody. Cancer Res 47:
947±52.
36 Thorpe PE,Wallace PM, Knowles PP,
et al. (1988) Improved anti-tumor effects
of immunotoxins prepared with
deglycosylated ricin-A chain and hindered
disulfide linkages. Cancer Res 48:
6396±403.
37 Moroney SE, O'Alarcao LJ, Goldmacher
VS, et al. (1987) Modification
of the binding site(s) of lectins by an affinity
column carrying an activated galactose-terminated
ligand. Biochemistry
26: 8390±8.
38 Thorpe PE, Ross WCJ, Brown ANF,
et al. (1984) Blockade of the galactosebinding
sites of ricin by its linkage to
antibody. Specific cytotoxic effects of the
conjugates. Eur J Biochem 140: 63±71.
39 Pasqualucci L,Wasik M, Teicher BA,
et al. (1995) Antitumor activity of anti-
CD30 immunotoxin (Ber-H2/saporin)
in vitro and in severe combined immunodeficiency
disease mice xenografted
with human CD30 + anaplastic large-cell
lymphoma. Blood 85: 2139±46.
40 Flavell OJ (1998) Saporin immunotoxins.
Curr Topics Microbiol Immunol 234:
57±61.
41 Uckun FM, Reaman GH (1995) Immunotoxins
for treatment of leukemia
and lymphoma. Leuk Lymph 18: 195±
201.
42 Irvin JO, Uckun FM (1992) Pokeweed
antiviral protein: ribosome inactivation
and therapeutic applications. Pharmacol
Ther 55: 279±302.
43 Greenfield L, Bjorn MJ, Horn G,
et al. (1983) Nucleotide sequence of the
structural gene for diphtheria toxin carried
by corynebacteriophage b. Proc
Natl Acad Sci USA 80: 6853±7.
44 Omura F, Kohno K, Uchida T (1989)
The histidine residue of codon 715 is
References
essential for function of elongation factor
2. Eur J Biochem 180: 1±8.
45 Wilson BA, Collier RJ (1992)
Diphtheria toxin and Pseudomonas aeruginosa
exotoxin A: active-site structure
and enzymic mechanism. Curr Topics
Microbiol Immunol 175: 27±41.
46 Williams DP,Wen Z,Watson RS,
Boyd J, Strom TB, Murphy JR (1990)
Cellular processing of the interleukin-2
fusion toxin DAB486±IL-2 and efficient
delivery of diphtheria fragment A to the
cytosol of target cells requires Arg194. J
Biol Chem 265: 20673±7.
47 Giannini G, Rappuoli R, Ratti G
(1984) The amino-acid sequence of two
non-toxic mutants of diphtheria toxin:
CRM45 and CRM197. Nucleic Acids Res
12: 4063±9.
48 Myers DA,Villemez CL (1988) Specific
chemical cleavage of diphtheria toxin
with hydroxylamine. Purification and
characterization of the modified proteins.
J Biol Chem 263: 17122±7.
49 Greenfield L, Johnson VG,Youle RJ
(1987) Mutations in diphtheria toxin separate
binding from entry and amplify
immunotoxin selectivity. Science 238:
536±9.
50 Choe S, Bennett MJ, Fujii G, et al.
(1992) The crystal structure of
diphtheria toxin. Nature 357: 216±22.
51 Sandvig K, Olsnes S (1980) Diphtheria
toxin entry into cells is facilitated by
low pH. J Cell Biol 87: 828±32.
52 Johnson VG,Youle RJ (1989) A point
mutation of proline 308 in diphtheria
toxin B chain inhibits membrane translocation
of toxin conjugates. J Biol
Chem 264: 17739±44.
53 Williams DP, Parker K, Bacha P, et al.
(1987) Diphtheria toxin receptor binding
domain substitution with interleukin-2:
genetic construction and properties
of a diphtheria toxin-related interleukin-2
fusion protein. Protein Eng 1:
493±8.
54 Iglewski BH, Kabat D (1975) NAD-dependent
inhibition of protein synthesis
by Pseudomonas aeruginosa toxin. Proc
Natl Acad Sci USA 72: 2284±8.
55 Allured VS, Collier RJ, Carroll SF,
McKay DB (1986) Structure of exotoxin
AofPseudomonas aeruginosa at 3.0 Ang-
371